Amyloidosis Research Consortium (ARC)
Kaushik Ghosal is an accomplished professional in the fields of strategic partnership and business development within the pharmaceutical and biotechnology sectors. Currently serving as the Director of Strategic Partnership and Business Development at the Amyloidosis Research Consortium since November 2024, Ghosal also holds a position on the Scientific Advisory Board of the Empire Discovery Institute, contributing expertise in drug discovery and commercialization strategies. Previous roles include VP and Head of Business Development at Dalriada Drug Discovery, and Director of Business Development at Evotec and BioMotiv, further showcasing experience in advancing innovative drug development projects. Ghosal co-founded and led BioExcel LLC as President, following a tenure as a Director of R&D at ReXceptor, where significant contributions to neurology therapeutic programs were made. Academic credentials include a Ph.D. in Neuroscience from Miami University and an MS in Biotechnology from the Indian Institute of Technology, Bombay.
This person is not in any teams
This person is not in any offices
Amyloidosis Research Consortium (ARC)
The Amyloidosis Research Consortium (ARC) addresses critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. We have created a collaborative research model to bring together experts in the field to address the challenges that exist in developing diagnostic tools and to carrying out innovative clinical trials. Stay up to date with the latest news and research from ARC's newsletter: http://www.arci.org/newsletter-sign-up ARC is committed to building collaborative relationships between patients, academia, industry, foundations, federal funders, and regulators to advance the best research and speed new therapies to market. ARC is focused on increasing the amount of research and building a prioritized portfolio of translational research and clinical research. The work of the Amyloidosis Research Consortium has been made possible through the generous support of our donors. With continued funding of our strategic and vital research programs, you are investing in a promising future for amyloidosis patients. You can donate here: www.arci.org/donate